Tharimmune: Panduan Proyek | Pembaruan Terbaru, Prapenjualan & Airdrop

Q: What is the Purpose of Tharimmune?

Tharimmune aims to develop innovative therapeutic candidates targeting immunology, inflammation, and oncology to address significant unmet medical needs, particularly in rare and orphan diseases.

Q: How Can I Participate in Tharimmune's Ecosystem?

Individuals can participate in Tharimmune's ecosystem by staying informed about the company's clinical trials and developments, investing in the company's stock if publicly traded, and exploring potential partnership or collaboration opportunities.

Q: What Sets Tharimmune Apart from Competitors?

Tharimmune's proprietary EpiClick™ Technology enables the development of multispecific biologics targeting unique epitopes against multiple solid tumors, offering novel mechanisms of action that may overcome resistance associated with existing therapies. Additionally, the company's focus on rare and orphan diseases addresses areas of significant unmet medical need.

Q: Is Tharimmune Secure?

Tharimmune implements rigorous security measures in its research and development processes, including compliance with regulatory standards and conducting thorough clinical trials to ensure the safety and efficacy of its therapeutic candidates.

Q: What are the Risks Associated with Tharimmune?

As with any clinical-stage biotechnology company, Tharimmune faces risks such as the potential for unsuccessful clinical trials, regulatory challenges, and the need for substantial funding to advance its pipeline. The company actively manages these risks through strategic planning, partnerships, and adherence to regulatory guidelines.

Beranda›
Beranda DApp›
Tharimmune

Tharimmune

Digital Asset Treasury Publicly listed company Crypto Stocks

Tharimmune, Inc. (THAR) is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology.

Unduh Aplikasi Bitget Wallet

What is Tharimmune?

Tharimmune is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation, and oncology. Its lead clinical asset, TH104, is being developed for specific indications, including respiratory and nervous system depression in military personnel and chemical incident responders exposed to high-potency opioids. The expanded pipeline includes other indications for TH104, such as chronic pruritus in primary biliary cholangitis, and TH023, a new approach to treating autoimmune diseases. Additionally, Tharimmune is advancing an early-stage multispecific biologic platform targeting unique epitopes against multiple solid tumors through its proprietary EpiClick™ Technology.

How Does Tharimmune Work?

Tharimmune's approach involves developing therapeutic candidates that target specific pathways implicated in various diseases. For instance, TH104 is designed to affect both the mu and kappa opioid receptors, which are involved in the body's itch circuitry, making it a potential treatment for chronic pruritus in primary biliary cholangitis. The company's EpiClick™ Technology enables the creation of multispecific biologics that can simultaneously engage multiple targets, offering a novel mechanism of action against solid tumors.

What Makes Tharimmune Unique?

Tharimmune's uniqueness lies in its proprietary EpiClick™ Technology, which allows for the development of multispecific biologics targeting unique epitopes against multiple solid tumors. This platform enables the creation of novel therapeutics with distinct mechanisms of action, potentially overcoming resistance associated with existing therapies. Additionally, Tharimmune's focus on developing treatments for rare and orphan diseases, such as primary biliary cholangitis, addresses significant unmet medical needs.

Who Are the Founders of Tharimmune?

Specific information about the founders of Tharimmune is not readily available in the provided sources. However, the company's executive management includes Randy Milby, who serves as the Chief Executive Officer. Mr. Milby has extensive experience in the biotechnology industry, leading Tharimmune's strategic initiatives and development programs.

Berita terbaru

What Key Events Have There Been for Tharimmune?

Tharimmune has achieved several significant milestones, including the initiation of a Phase 1 clinical trial for TH104, its lead candidate for pruritus in primary biliary cholangitis. The company also announced positive results from this trial, demonstrating a favorable safety and tolerability profile. Additionally, Tharimmune was granted a European patent for its biodegradable polymeric nanoparticles designed to enhance the delivery of therapeutic antibodies and peptides, particularly in cancer therapies.

Project Announcements

Tharimmune announced the expansion of its product pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both Programmed Death-1 (PD-1) and Vascular Endothelial Growth Factor (VEGF) receptors. Utilizing its proprietary EpiClick™ Technology, HS1940 represents a key expansion of Tharimmune's product pipeline and underscores the company's commitment to addressing unmet needs in oncology.

Acara mendatang

Tidak ada data

Pengumuman proyek

Where to Buy Tharimmune?

Tharimmune Price

Daily Trading Volume

All-Time High

All-Time Low

Market Cap and Valuation

Market Cap

Fully Diluted Valuation

Tharimmune Price Prediction

Currently, there are no available forecasts from reliable experts or publications regarding Tharimmune's price prediction.

FAQ

What is the Purpose of Tharimmune?

How Can I Participate in Tharimmune's Ecosystem?

What Sets Tharimmune Apart from Competitors?

Is Tharimmune Secure?

What are the Risks Associated with Tharimmune?

Penafian & pemberitahuan risiko: Sebagian konten di halaman ini mungkin dibantu atau dibuat oleh AI dan hanya untuk referensi umum. Untuk informasi yang paling akurat dan terbaru, silakan merujuk ke situs web resmi proyek. Bitget Wallet menghargai setiap kemitraan. Jika Anda menemukan masalah atau ketidakakuratan, hubungi kami di [email protected] — kami menghargai masukan Anda dan akan terus melakukan perbaikan.